Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Alicante (153)

2024

  1. Adherence to periprocedural antithrombotic treatment recommendations and its prognostic impact in patients with high ischemic and hemorrhagic risk

    Revista Espanola de Cardiologia

  2. Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy

    Medicina Clinica, Vol. 163, Núm. 7, pp. 336-343

2023

  1. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in “real world”: the REQXAA study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 729-738

2022

  1. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 4

  2. Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors

    Diabetes Research and Clinical Practice, Vol. 184

  3. Current trends on antithrombotic therapy

    REC: CardioClinics

2021

  1. Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome

    Revista Espanola de Cardiologia, Vol. 74, Núm. 9, pp. 765-772

  2. Impact of comorbidities in the decision of using invasive management in elderly patients with NSTEACS

    REC: Interventional Cardiology, Vol. 3, Núm. 1, pp. 15-20

  3. Prognosis impact of diabetes in elderly women and men with non-st elevation acute coronary syndrome

    Journal of Clinical Medicine, Vol. 10, Núm. 19

2020

  1. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: Results from a prospective and multicentre ACHILLES registry

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1052-1061

  2. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology

    Revista Espanola de Cardiologia, Vol. 73, Núm. 9, pp. 749-757

2019

  1. Chronic Kidney Disease and Third-Generation P2Y 12 Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year

    Journal of Clinical Pharmacology, Vol. 59, Núm. 2, pp. 295-302

  2. Switching of Oral P2Y 12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis

    Clinical Drug Investigation, Vol. 39, Núm. 3, pp. 275-283

  3. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

  4. Galectin-3 and β-trace protein concentrations are higher in clinically unaffected patients with Fabry disease

    Scientific Reports, Vol. 9, Núm. 1

  5. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome

    European Journal of Internal Medicine, Vol. 61, pp. 48-53

  6. Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease

    Minerva Medica, Vol. 110, Núm. 5, pp. 410-418

2018

  1. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA 2 DS 2 -VASc and HAS-BLED scores using multiple biomarkers

    Annals of Medicine, Vol. 50, Núm. 1, pp. 26-34

  2. Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines

    PLoS ONE, Vol. 13, Núm. 11

  3. Disparities in the estimation of glomerular filtration rate according to cockcroft-gault, modification of diet in renal disease-4, and chronic kidney disease epidemiology collaboration equations and relation with outcomes in patients with acute coronary syndrome

    Journal of the American Heart Association, Vol. 7, Núm. 9